The drug, zocilurtatug pelitecan, demonstrated a favorable safety profile when administered alongside an immunotherapy treatment for patients undergoing initial care. Rafael Amado, president and head of global research and development, noted that the confirmed response rates and the durability of the chemotherapy-free regimen were particularly compelling findings from the study.

Following these results, the company is shifting its focus toward a global phase 3 trial. Leadership is also evaluating additional immuno-oncology combinations to expand the drug's potential reach in cancer treatment.